naxitamab   Click here for help

GtoPdb Ligand ID: 11341

Synonyms: DANYELZA® | hu3F8 | naxitamab-gqgk
Approved drug
naxitamab is an approved drug (FDA (2020))
Compound class: Antibody
Comment: Naxitamab (hu3F8) is a humanized monoclonal antibody that targets ganglioside GD2 that was developed by Y-mAbs Therapeutics for potential to treat high risk neuroblastoma [1-2]. GD2 is a sialised glycosphingolipid cell adhesion molecule, that is highly expressed on neuroectoderm-derived tumours and sarcomas, including neuroblastoma, retinoblastoma, melanoma and small cell lung cancer [7]. Naxitamab stimulates antibody-dependent cell-mediated cytotoxicity (ADCC) against GD2-expressing tumour cells [5].
Protein BLAST analysis of the peptide sequences of the heavy and light chains from the INN submission for naxitamab, show 100% matches with sequences in patent US10167341B2, which claims 'High affinity anti-GD2 antibodies' [4]. From sequence comparisons, naxitamab would appear to be referred to as hu3F8V1 in this patent.
Classification Click here for help
Compound class Antibody
Approved drug? Yes. FDA (2020)
International Nonproprietary Names Click here for help
INN number INN
10918 naxitamab
Synonyms Click here for help
DANYELZA® | hu3F8 | naxitamab-gqgk
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 890
Other databases
GtoPdb PubChem SID 440816710
Search PubMed clinical trials naxitamab
Search PubMed titles naxitamab
Search PubMed titles/abstracts naxitamab